Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Researchers from University of Frankfurt report on findings in cancer gene therapy
May 27th, 2008
Researchers detail in 'Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models,' new data in cancer gene therapy. "Survivin shows a radiation resistance factor in colorectal cancer. In the present study, we determined whether survivin messenger RNA levels in patients with rectal cancer predict tumor response after neoadjuvant radiochemotherapy and whether inhibition of survivin by the use of antisense oligonucleotides (ASOs) enhances radiation responses," scientists in Frankfurt, Germany report. "SW480 colorectal carcinoma cells were transfected with survivin ASO (LY2181308) and irradiated...
Source: Cancer Weekly (2008-05-27)
|
